Acclarent

Join us in New Orleans at #ARS2024! We’re excited to attend ARS Summer Sinus Symposium in New Orleans and look forward to connecting with you. Be sure to stop by Booth #S3 at the Hyatt Regency to meet the Acclarent and broader Integra LifeSciences teams. See you there! #Acclarent #ARS2024 #ENT

This #MemorialDay, Integra LifeSciences and our Integra Veterans Affinity Group (IVAG) remembers with gratitude those who made the ultimate sacrifices for their countries. Thank you to all service members and their families.

Think beyond ear tubes. When ear tubes are not enough, treat the source not the symptoms for enduring ETD relief. ACCLARENT AERA® is the first device exclusively designed with strong focus on safety features and is the only ETBD device FDA cleared for certain patients ages 8 and above. Contact your local Acclarent rep for a demonstration. Please refer to our IFU to learn about the indicated population: https://lnkd.in/g2PA2BGH  #Acclarent #AERAPediatrics #ETBD

Join us in Chicago, we’re heading to #COSM2024! Our team is excited to attend this year’s COSM and look forward to connecting with you. Be sure to stop by our Main Booth 208 and Technology Suite BS2 at the Hyatt Regency to experience our leading-edge innovations. See you soon! #Acclarent #COSM2024 #ENT

Integra LifeSciences completes the acquisition of Acclarent. We are excited to welcome our new colleagues and together, we will continue to innovate treatment pathways to advance patient outcomes and set new standards of care. #IntegraInspired Read the press release: https://ow.ly/nUqc50R63m6.

ACCLARENT AERA® is the first device exclusively designed to treat persistent Eustachian tube dysfunction with a strong focus on safety features. With a 97.7% success rate in dilating the Eustachian tube, ACCLARENT AERA® is now FDA cleared for certain patients ages 8 and above. ACCLARENT AERA® preserves natural anatomy with minimally invasive, transnasal access; offers the flexibility to adapt to the s-shaped curve of the Eustachian tube; and is designed specifically for the Eustachian tube anatomy. Contact your local Acclarent rep to learn more. Please refer to our IFU to learn about the indicated population: https://lnkd.in/g2PA2BGH #Acclarent #AERAPediatrics #ETBD

In-office balloon sinus dilation procedures eliminate the risks associated with general anesthesia performed in the hospital. It can present considerable cost-saving potential when compared to traditional sinus procedures performed in a hospital. Michael Freedman, MD, explains how balloon sinuplasty can treat sinusitis in a minimally invasive way.  Learn more: https://lnkd.in/gjmzKdgs #Acclarent #BalloonSinuplasty #BSP #ENT

Our team came together for the 2024 National Training Meeting in Fort Lauderdale. We had an amazing time connecting with each other and celebrating the many milestones and victories this past year. Congratulations to all award recipients! We used our time together to share insights, knowledge, and field experiences to find even better ways to partner with physicians in our pursuit to improve the quality of life for the many patients that depend on our technologies. Whitney and her son, Jase, a young active patient from Texas, also spent time with our team and shared his journey in overcoming obstructive Eustachian tube dysfunction (OETD) with the help of the ACCLARENT AERA© ETBD device. Our team was so inspired by his courage and story. High five, Jase, for giving us a reason to do what we do! Thank you to all our employees for all that you do for clinicians and patients! Team Acclarent, you rock! #Acclarent #2024NTM

Dr. Margaret Butler is recognized as a pioneer in otolaryngology. She was an American physician who chaired the otorhinolaryngology department at the Women's Medical College of Pennsylvania. In 1908, she became the first woman to be elected honorary president and to preside over the International Congress of Laryngology and Rhinology. As a fellow of the American College of Surgeons, she became a legend in her field, developing medical devices and techniques that revolutionized the treatment of the ear, nose, and throat (ENT). Here’s to the trailblazers, including the women at Acclarent and our partners, who have continued to push ENT forward and make our world a better place for all! We celebrate you! #CelebrateWomensDay #Acclarent #Inspiration

ACCLARENT AERA® is now FDA cleared for certain pediatric patients ages 8 and above. Instead of recurrent ear tube procedures, consider an alternative treatment with ACCLARENT AERA®, the only ETBD device indicated for children. A retrospective analysis of real-world data suggested a failure-free rate of 84% after a mean of 2.7 years of follow-up*1. ACCLARENT AERA® was designed with a strong focus on safety! Contact your local Acclarent rep for a demonstration to learn more. Please refer to our IFU to learn about the indicated population: https://lnkd.in/g2PA2BGH  #Acclarent #AERAPediatrics #ETBD  * Failure is defined as whether further surgery was needed to treat the patient's ETD, e.g., tympanostomy tube insertion or revision ETBD.  1. Traditional 510(k): Device Labeling Modification to ACCLARENT AERA® Eustachian Tube Balloon System, (K230742), dated December 13, 2023.